20 June 2014 : Original article
Comparison of conventional tacrolimus versus prolong release formula as initial therapy in heart transplantation
Tomasz UrbanowiczABCDEF, Hanna Baszyńska-WachowiakBC, Marcin LigowskiBCD, Ewa Straburzyńska-MigajBCD, Marcin MisterskiB, Marek JemielityABCDDOI: 10.12659/AOT.890268
Ann Transplant 2014; 19:295-299
Abstract
BACKGROUND: A new formulation of tacrolimus that is characterized by prolonged release has been developed to facilitate treatment and patient compliance. Initial therapy with prolonged release formula in heart transplantation is not widely accepted.
MATERIAL AND METHODS: We enrolled 19 patients into a randomized analysis divided into 2 groups with different initial regimens. There were 8 patients with a mean age of 44±13 years treated by Advagraf, and 11 patients with a mean age of 41±9 years treated by Prograf. Serum concentration of immunosuppressive drug was followed by its oral dosage and endomyocardial biopsy results. Arterial hypertension, kidney function, and incidence of diabetes mellitus were recorded.
RESULTS: There were no perioperative deaths. The risk of acute rejection within 6 months following surgery was 1 (2%) in the Advagraf group and 1 (1.5%) in the Prograf group. Although the serum tacrolimus results were comparable between groups, the drug’s daily dosages were different after 6 months of therapy (3±1 mg in the Advagraf group and 6±2 mg in the Prograf group (p<0.05). The low rate of adverse effects throughout the study was noted.
CONCLUSIONS: Prolonged-release tacrolimus formula is an efficient immunosuppressant in heart transplantation. Its initial application after surgery has low risk of adverse effects with similar results to conventional formula.
Keywords: Heart Transplantation, Biopsy, Tacrolimus
SARS-CoV-2/COVID-19
17 June 2022 : Case report
Extrapulmonary Manifestations of SARS-CoV-2: A Report of 3 Cases and a Literature ReviewAnn Transplant In Press; DOI: 10.12659/AOT.935874
12 April 2022 : Letter/Correspondence
Pancreas Allograft Thrombosis as a Post-COVID-19 Complication in a Diabetic Patient After Pancreas Transpla...Ann Transplant 2022; 27:e935863
12 November 2021 : Original article
Coronavirus Disease 2019 (COVID-19) in Solid Organ Transplant Recipients: A Case-Control StudyAnn Transplant 2021; 26:e933152
26 October 2021 : Original article
Safety of Antithymocyte Globulin Use in Kidney Graft Recipients During the COVID-19 PandemicAnn Transplant 2021; 26:e933001
In Press
23 Jun 2022 : Original article
Evaluation of Deceased Donor Kidney Transplantation in the Eurotransplant Senior Program in Comparison to S...Ann Transplant In Press; DOI: 10.12659/AOT.936514
21 Jun 2022 : Case report
Extrapulmonary Manifestations of SARS-CoV-2: A Report of 3 Cases and a Literature ReviewAnn Transplant In Press; DOI: 10.12659/AOT.935874
20 Jun 2022 : Original article
The Association Between Tacrolimus Levels and Hyperkalemia in Allograft Recipients Who Underwent Heart or L...Ann Transplant In Press; DOI: 10.12659/AOT.935607
15 Jun 2022 : Original article
Donor CYP3A5 Expression Decreases Renal Transplantation Outcomes in White Renal Transplant RecipientsAnn Transplant In Press; DOI: 10.12659/AOT.936276
Most Viewed Current Articles
26 Jan 2022 : Review article
Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive ModelsDOI :10.12659/AOT.934924
Ann Transplant 2022; 27:e934924
29 Dec 2021 : Original article
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588
24 Jul 2020 : Review article
Kidney Transplantation in the Times of COVID-19 – A Literature ReviewDOI :10.12659/AOT.925755
Ann Transplant 2020; 25:e925755
15 Mar 2022 : Case report
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860